贝伐珠单抗联合含铂化疗方案治疗肺腺癌恶性胸腔积液患者的效果观察  

Observation on the Effect of Bevacizumab Combined with Platinumcontaining Chemotherapy in the Treatment of Patients with Malignant Pleural Effusion of Lung Adenocarcinoma

作　　者：贾要丽 周晓蕾[1] 张博 张曼林[1] JIA Yaoli;ZHOU Xiaolei;ZHNAG Bo;ZHANG Manlin(Department of Respiratory Medicine,Henan Provincial Chest Hospital,Zhengzhou 450000,Henan,China)

机构地区：[1]河南省胸科医院呼吸内科,河南郑州450000

出　　处：《中国药物滥用防治杂志》2024年第10期1851-1854,共4页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：河南省医学科技攻关计划项目(编号:LHGJ20210230)。

摘　　要：目的:研究贝伐珠单抗联合含铂化疗方案对肺腺癌恶性胸腔积液(MPE)患者免疫功能、近期疗效的影响。方法:选择2023年5月—2024年5月本院收治的110例肺腺癌MPE患者为研究对象,随机分为对照组和观察组,每组55例。对照组行含铂化疗,观察组行贝伐珠单抗联合含铂化疗,比较两组近期疗效、免疫功能、肿瘤标志物水平[血管内皮生长因子(VEGF)、低氧诱导因子-1α(HIF-1α)、癌胚抗原(CEA)]。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后NK、CD3^(+)、CD4^(+)高于对照组,VEGF、HIF-1α、CEA低于对照组,差异有统计学意义(P<0.05)。结论:贝伐珠单抗联合含铂化疗治疗肺腺癌MPE,能尽快排出积液,改善免疫功能。Objective:To study the effect of bevacizumab combined with platinum-containing chemotherapy on immune function and short-term efficacy in patients with malignant pleural effusion(MPE)of lung adenocarcinoma.Methods:A total of 110 patients with lung adenocarcinoma MPE admitted to our hospital from May 2023 to May 2024 were randomly divided into control group and observation group,with 55 patients in each group.The control group was treated with platinum-containing chemotherapy,and the observation group was treated with bevacizumab combined with platinum-containing chemotherapy.The short-term efficacy,immune function,and tumor marker levels[vascular endothelial growth factor(VEGF),hypoxia-inducible factor-1α(HIF-1α),carcinoembryonic antigen(CEA)]were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,NK,CD3^(+)and CD4^(+)in the observation group were higher than those in the control group,VEGF,HIF-1αand CEA were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Bevacizumab combined with platinum-containing chemotherapy in the treatment of lung adenocarcinoma MPE can discharge effusion as soon as possible and improve immune function.

关 键 词：肺腺癌恶性胸腔积液 贝伐珠单抗 含铂化疗 免疫功能 近期疗效 

分 类 号：R734.2[医药卫生—肿瘤]